Dacetuzumab

Drug Profile

Dacetuzumab

Alternative Names: huS2C6; PRO 64553; RG 3636; S2C6 monoclonal antibody; SGN 14; SGN-40

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Seattle Genetics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 05 Aug 2011 Discontinued - Phase-I for Multiple myeloma in European Union (IV)
  • 05 Aug 2011 Discontinued - Phase-I for Multiple myeloma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top